oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciencesoncotomsk-225Research ArticleОБЗОРЫREVIEWSСОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ ПОСЛЕОПЕРАЦИОННОЙ ЛУЧЕВОЙ ТЕРАПИИ РАКА ЛЕГКОГОCURRENT STATE OF POSTOPERATIVE RADIOTHERAPY OF LUNG CANCERРагулинЮ. А.RagulinYu. A.

Рагулин Юрий Александрович, кандидат медицинских наук, заведующий отделением лучевого и хирургического лечения заболеваний торакальной области с группой лечения заболеваний молочной железы.

Тел.: 8 905 641-87-80. E-mail: yuri.ragulin@mail.ru. SPIN-код: 6453-6594

Ragulin Yuriy Alexandrovich, MD, PhD, Head of Department of Radiation and Surgical Treatment of Diseases of Thoracic Region with Group of Treatment of Breast Cancer. 

Phone: +7 905 641-87-80. E-mail: yuri.ragulin@mail.ru. SPIN-code: 6453-6594

uri.ragulin@mail.ruМедицинский радиологический научный центр им. А.Ф. Цыба – филиал ФБУН «Национальный медицинский исследовательский радиологический центр», ОбнинскРоссияA.F. Tsyba Medical Radiological Research Center affiliated to P.A. Gertsen Moscow Cancer Research Institute, ObninskRussian Federation201521022016146872Copyright © Рагулин Ю.А., 20162016Рагулин Ю.А.Ragulin Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/225

В проблеме адъювантного лечения немелкоклеточного рака легкого остается много нерешенных вопросов, наибольшие дискуссии вызывает послеоперационная лучевая терапия (ПОЛТ). За последние десятилетия произошли существенные изменения в оценке результатов лечения и определении показаний к использованию различных методик. Совершенствование диагностических методов в предоперационном стадировании заболевания и использование современной радиологической аппаратуры позволяет улучшить показатели выживаемости больных операбельным немелкоклеточным раком легкого с метастазами в медиастинальных лимфоузлах. Представлены результаты наиболее значимых исследований по изучению ПОЛТ с акцентом на применение современных технологий диагностики и лечения. Продолжающиеся рандомизированные исследования позволят получить новые сведения об эффективности ПОЛТ. 

The problem adjuvant treatment of non-small cell lung cancer there are many unresolved questions, postoperative radiation therapy (PORT) is more controversial. Over the last decade there have been significant changes in the assessment of treatment results and treatment indications. Improvements in diagnostics of preoperative staging and the use of modern radiological technics improve survival in patients with resectable non-small cell lung cancer with mediastinal lymph nodes metastasis. This article presents the results of the most significant studies PORT with the modern technologies of diagnostics and treatment. Ongoing randomized trials will provide new data on the effectiveness of PORT.

немелкоклеточный рак легкогопослеоперационная лучевая терапияnon-small cell lung cancerpostoperative radiation therapyReferencesКолбанов К.И., Трахтенберг А.Х., Бойко А.В., Пикин О.В., Глушко В.А. Хирургическое и комбинированное лечение больных немелкоклеточным раком легкого IIIА–В стадии // Онкология. 2013. Т. 1. № 5. С. 4–9.Kolbanov K.I., Trakhtenberg A.Kh., Boyko A.V., Pikin O.V., Glushko V.A. Surgical and combination treatments in patients with Stage IIIA-B non-small cell lung carcinoma // Onkologiya. 2013. Vol. 1 (5). P. 4–9. [in Russian]Baumann M., Herrmann T., Koch R., Matthiessen W., Appold S., Wahlers B., Kepka L., Marschke G., Feltl D., Fietkau R., Budach V., Dunst J., Dziadziuszko R., Krause M., Zips D. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionatedaccelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC) // Radiother. Oncol. 2011. Vol. 100 (1). P. 76–85. doi: 10.1016/j.radonc.2011.06.031.Baumann M., Herrmann T., Koch R., Matthiessen W., Appold S., Wahlers B., Kepka L., Marschke G., Feltl D., Fietkau R., Budach V., Dunst J., Dziadziuszko R., Krause M., Zips D. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionatedaccelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC) // Radiother. Oncol. 2011. Vol. 100 (1). P. 76–85. doi: 10.1016/j.radonc.2011.06.031.Bekelman J., Rosenzweig K., Bach P., Schrag D. Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer // Int. J. Radiat. Oncol. Biol. Phys. 2006. Vol. 66 (2). P. 492–499.Bekelman J., Rosenzweig K., Bach P., Schrag D. Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer // Int. J. Radiat. Oncol. Biol. Phys. 2006. Vol. 66 (2). P. 492–499.Billiet C., Decaluwé H., Peeters S., Vansteenkiste J., Dooms C., Haustermans K., De Leyn P., De Ruysscher D. Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: a meta-analysis // Radiother. Oncol. 2014. Vol. 110 (1). P. 3–8. doi: 10.1016/j.radonc.2013.08.011.Billiet C., Decaluwé H., Peeters S., Vansteenkiste J., Dooms C., Haustermans K., De Leyn P., De Ruysscher D. Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: a meta-analysis // Radiother. Oncol. 2014. Vol. 110 (1). P. 3–8. doi: 10.1016/j.radonc.2013.08.011.Bogart J., Aronowitz J. Localized non-small cell lung cancer: adjuvant radiotherapy in the era of effective systemic therapy // Clin. Cancer Res. 2005. Vol. 11. P. 5004–5010.Bogart J., Aronowitz J. Localized non-small cell lung cancer: adjuvant radiotherapy in the era of effective systemic therapy // Clin. Cancer Res. 2005. Vol. 11. P. 5004–5010.Corso C.D., Rutter C.E., Wilson L.D., Kim A.W., Decker R.H., Husain Z.A. Re-evaluation of the role of post-operative radiotherapy and the impact of radiation dose for non-small cell lung cancer using the National Cancer Database // J. Thorac. Oncol. 2015. Vol. 10 (1):148-55. doi: 10.1097/JTO.0000000000000406.Corso C.D., Rutter C.E., Wilson L.D., Kim A.W., Decker R.H., Husain Z.A. Re-evaluation of the role of post-operative radiotherapy and the impact of radiation dose for non-small cell lung cancer using the National Cancer Database // J. Thorac. Oncol. 2015. Vol. 10 (1):148-55. doi: 10.1097/JTO.0000000000000406.Decker R., Wilson L. Postoperative radiation therapy for nonsmall cell lung cancer // Semin. Thorac. Cardiovasc. Surg. 2008. Vol. 20. P. 184–187.Decker R., Wilson L. Postoperative radiation therapy for nonsmall cell lung cancer // Semin. Thorac. Cardiovasc. Surg. 2008. Vol. 20. P. 184–187.Douillard J., Rosell R., De Lena M., Riggi M., Hurteloup P., Mahe M. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial // Int. J. Radiat. Oncol. Biol. Phys. 2008. Vol. 72. P. 695–701. doi: 10.1016/j.ijrobp.2008.01.044.Douillard J., Rosell R., De Lena M., Riggi M., Hurteloup P., Mahe M. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial // Int. J. Radiat. Oncol. Biol. Phys. 2008. Vol. 72. P. 695–701. doi: 10.1016/j.ijrobp.2008.01.044.Heon S., Johnson B.E. Adjuvant chemotherapy for surgically resected non-small cell lung cancer // J. Thorac. Cardiovasc. Surg. 2012. 144 (3). P. 39–42. doi: 10.1016/j.jtcvs.2012.03.039.Heon S., Johnson B.E. Adjuvant chemotherapy for surgically resected non-small cell lung cancer // J. Thorac. Cardiovasc. Surg. 2012. 144 (3). P. 39–42. doi: 10.1016/j.jtcvs.2012.03.039.Kal H.B., El Sharouni S.Ya., Struikmans H. Postoperative radiotherapy in non-small-cell lung cancer // The Lancet. 1998. Vol. 352 (9137). P. 1385–1386.Kal H.B., El Sharouni S.Ya., Struikmans H. Postoperative radiotherapy in non-small-cell lung cancer // The Lancet. 1998. Vol. 352 (9137). P. 1385–1386.Lally B., Zelterman D., Colasanto J., Haffty B., Detterbeck F., Wilson L. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database // J. Clin. Oncol. 2006. Vol. 24. P. 2998–3006.Lally B., Zelterman D., Colasanto J., Haffty B., Detterbeck F., Wilson L. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database // J. Clin. Oncol. 2006. Vol. 24. P. 2998–3006.Leong D., Rai R., Nguyen B., Lee A., Yip D. Advances in adjuvant systemic therapy for non-small-cell lung cancer // World J. Clin. Oncol. 2014. Vol. 5 (4). P. 633–645. doi: 10.5306/wjco.v5.i4.633.Leong D., Rai R., Nguyen B., Lee A., Yip D. Advances in adjuvant systemic therapy for non-small-cell lung cancer // World J. Clin. Oncol. 2014. Vol. 5 (4). P. 633–645. doi: 10.5306/wjco.v5.i4.633.Le Péchoux C. Role of postoperative radiotherapy in resected nonsmall cell lung cancer: a reassessment based on new data // Oncologist. 2011. Vol. 16 (5). P. 672–681. doi: 10.1634/theoncologist.2010-0150.Le Péchoux C. Role of postoperative radiotherapy in resected nonsmall cell lung cancer: a reassessment based on new data // Oncologist. 2011. Vol. 16 (5). P. 672–681. doi: 10.1634/theoncologist.2010-0150.Machtay M. Postoperative radiotherapy in non-small-cell lung cancer // The Lancet. 1998. Vol. 352 (9137). P. 1384–1385.Machtay M. Postoperative radiotherapy in non-small-cell lung cancer // The Lancet. 1998. Vol. 352 (9137). P. 1384–1385.Mikell J.L., Gillespie T.W., Hall W.A., Nickleach D.C., Liu Y., Lipscomb J., Ramalingam S.S., Rajpara R.S., Force S.D., Fernandez F.G., Owonikoko T.K., Pillai R.N., Khuri F.R., Curran W.J., Higgins K.A. Post-Operative Radiotherapy (PORT) is Associated with Better Survival in Non-Small Cell Lung Cancer with Involved N2 Lymph Nodes: Results of an Analysis of the National Cancer Data Base // J. Thorac. Oncol. 2015. Vol. 10 (3). P. 462–471. doi: 10.1097/JTO.0000000000000411.Mikell J.L., Gillespie T.W., Hall W.A., Nickleach D.C., Liu Y., Lipscomb J., Ramalingam S.S., Rajpara R.S., Force S.D., Fernandez F.G., Owonikoko T.K., Pillai R.N., Khuri F.R., Curran W.J., Higgins K.A. Post-Operative Radiotherapy (PORT) is Associated with Better Survival in Non-Small Cell Lung Cancer with Involved N2 Lymph Nodes: Results of an Analysis of the National Cancer Data Base // J. Thorac. Oncol. 2015. Vol. 10 (3). P. 462–471. doi: 10.1097/JTO.0000000000000411.Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group // Lancet. 1998. Vol. 352 (9124). P. 257–263.Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group // Lancet. 1998. Vol. 352 (9124). P. 257–263.Rowell N.P. Postoperative radiotherapy in non-small-cell lung cancer // The Lancet. 1998. Vol. 352 (9137). P. 1384.Rowell N.P. Postoperative radiotherapy in non-small-cell lung cancer // The Lancet. 1998. Vol. 352 (9137). P. 1384.Soliman M., Yaromina A., Appold S., Zips D., Reiffenstuhl C., Schreiber A., Thames H.D., Krause M., Baumann M. GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial // Radiother Oncol. 2013. Vol. 106 (3). P. 299–304. doi: 10.1016/j.radonc.2012.12.008Soliman M., Yaromina A., Appold S., Zips D., Reiffenstuhl C., Schreiber A., Thames H.D., Krause M., Baumann M. GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial // Radiother Oncol. 2013. Vol. 106 (3). P. 299–304. doi: 10.1016/j.radonc.2012.12.008Wakelee H., Stephenson P., Keller S., Wagner H., Herskovic A., Komaki R., Marks R.S., Perry M.C., Livingston R.B., Johnson D.H. Postoperative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590 // Lung Cancer. 2005. Vol. 48 (3). P. 389–397.Wakelee H., Stephenson P., Keller S., Wagner H., Herskovic A., Komaki R., Marks R.S., Perry M.C., Livingston R.B., Johnson D.H. Postoperative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590 // Lung Cancer. 2005. Vol. 48 (3). P. 389–397.

The authors declare that there are no conflicts of interest present.